Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are:

1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom;
2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metabolic Changes in Healthy Subjects with Acute Binge Drink

NCT06298318

Binge Drinking Liver Injury Hepatic Steatosis

COMPLETED PHASE1

Rapid BAC Reduction with Nutraceutical Blend Study

NCT06722898

Alcohol Consumption Alcohol Hangover Symptoms, NAC +1 more

NOT_YET_RECRUITING PHASE2

Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease

NCT03847116

Nonalcoholic Fatty Liver Disease Light-to-moderate Alcohol Consumption Type2 Diabetes Mellitus

COMPLETED

Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers

NCT05551754

Alcohol Drinking

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Effects Ketone Supplement and Alcohol on Brain Metabolism

NCT06815237

Ketosis Alcohol Drinking MRI

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are:

1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom;
2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

Participants will be randomized into two groups (n=20), and take 4 NMN capsules (250mg/capsule) or 4 placebo capsules (maltodextrin), respectively. 15 minutes later, they are successively provided with same breakfast and then vodka with a dose of 1g/kg body weight. Venous blood are collected at 0h, 1h, 2h, 3h, 4h, 8h, 12h and 24h from each subject, respectively. In addition, nuclear magnetic resonance imaging (MRI) are taken at 0h, 4h and 24h after alcohol intake. After a 7-day washout period, volunteers are crossed over to another alternative group to receive the corresponding capsules and the test protocol repeats twice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Binge Drinking Liver Injury Nutritional Supplementation Hepatic Steatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Intervention method using β-nicotinamide mononucleotide

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

maltodextrin group

4 capsule with 1000mg ''maltodextrin''

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.

β-nicotinamide mononucleotide group

4 capsule with 1000mg ''β-nicotinamide mononucleotide''

Group Type EXPERIMENTAL

β-nicotinamide Mononucleotide

Intervention Type DIETARY_SUPPLEMENT

After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

β-nicotinamide Mononucleotide

After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NMN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

a. Sign informed consent

Exclusion Criteria

1. Neurological disorders
2. Alcohol allergy
3. Alcohol addiction
4. Gastrointestinal diseases
5. Liver, kidney, cardiovascular or systemic diseases
6. Antibiotics were administered within 2 weeks prior to the trial
7. Participants who ate a vegetarian diet
8. Unable to use a smartphone or computer with Internet access
9. Participate in another intervention study

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes